Please assess the completion status of the following clinical trial:

Trial Title: SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
The trial entry criteria are based on:~1. A diagnosis of definite NAFLD on liver biopsy obtained within 3 months of screening.~2. ≥20 years of age at the time of the initial screening.~3. Patients with type 2 diabetes mellitus at the time of screening need to have glycemic control (HbA1c of ≥7%) and have been managed by either diet and/or a stable dose of hypoglycemic agents for at least 4 weeks.~Exclusion Criteria~1. Hepatic virus infections (hepatitis B and C, cytomegalovirus, and Epstein-Barr virus), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha 1-antitrypsin deficiency, Wilson's disease, history of parenteral nutrition.~2. Use of agents known to induce steatosis (e.g., valproate, amiodarone, or vitamin E)~3. Hepatic injury caused by substance abuse.~4. Current consumption of more than 20 g of alcohol daily.~5. Hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding~6. Elevated serum bilirubin level of more than two-fold the upper normal limit.~7. Tofogliflozin or glimepiride hypersensitivity or contraindications.~8. History of type 1 diabetes.~9. History of ketoacidosis.~10. History of symptoms of severe hypoglycemia.~11. Treatment with SGLT2 inhibitor including tofogliflozin within 4 weeks of screening.~12. Treatment with glinide and sulfonylurea use within 4 weeks of screening.~13. Concomitant corticosteroid therapy uses within 4 weeks of screening.~14. Poorly controlled unstable diabetes (ketoacidosis or an increase in HbA1c of \>3% in the 12 weeks before screening).~15. Poorly controlled hypertension or systolic blood pressure of \>160 mmHg or diastolic blood pressure of \>100 mmHg.~16. Artificial dialysis or moderate renal dysfunction.~17. Poorly controlled dyslipidemia.~18. Presence of a severe health problem, not being suitable for the study.~19. Pregnant or breastfeeding.~20. Inability to participate in the study (including psychiatric and psychosocial problems), as assessed by the investigators.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2 inhibitor (Type: ACTIVE_COMPARATOR): N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).